View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest, Korányi Sándor u. 2/a, 1083
  • | 2 McGill University, Montreal, Kanada
  • | 3 Semmelweis Egyetem, Egészségtudományi Kar, Budapest
Open access

Absztrakt:

Az elmúlt évtizedben a gastrointestinalis kórképek diagnosztikája sokat változott. Az endoszkópos és képalkotó módszerek mellett előtérbe kerültek a gyorsan elvégezhető laboratóriumi diagnosztikus vizsgálatok is. Külön előnynek számít, ha a vizsgálat könnyen ismételhető, így a krónikus betegségek követésére, az esetleges fellángolások időben történő felismerésére is alkalmas lehet. A székletkalprotektin meghatározása, mely más országokban már a mindennapi diagnosztika része, hazánkban is egyre több helyen hozzáférhető. Összefoglaló közleményünkben bemutatjuk a székletkalprotektin-vizsgálat szerepét és megbízhatóságát a gasztroenterológiai kórképekben, különös tekintettel a gyulladásos bélbetegségekre, a bélrendszeri fertőzésekre, az irritábilisbél-szindrómára és egyes gyermek gasztroenterológiai kórképekre. A különböző betegségekben és helyzetekben használatos határértékeknek és az ezekhez tartozó specificitásnak és szenzitivitásnak a bemutatásával szeretnénk segíteni a klinikai orvosokat a helyes döntéshozatalban. Orv Hetil. 2019; 160(9): 322–328.

  • 1

    Naismith GD, Smith LA, Barry SJ, et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn’s disease. Aliment Pharmacol Ther. 2013; 37: 613–621.

  • 2

    Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013; 17: 1–211.

  • 3

    Caviglia GP, Ribaldone DG, Rosso C, et al. Fecal calprotectin: beyond intestinal organic diseases. Panminerva Med. 2018; 60: 29–34.

  • 4

    Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999; 34: 50–54.

  • 5

    Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003; 49: 861–867.

  • 6

    von Roon A, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007; 102: 803–813.

  • 7

    van Rheenen FP, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.

  • 8

    Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014; 109: 637–645.

  • 9

    Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010; 105: 162–169.

  • 10

    Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013; 19: 332–341.

  • 11

    Lin J, Chen J, Zuo J, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014; 20: 1407–1415.

  • 12

    García-Sánchez V, Iglesias-Flores E, González R, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis 2010; 4:144–152.

  • 13

    Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012; 18: 1894–1899.

  • 14

    De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013; 19: 2111–2117.

  • 15

    Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015; 110: 1324–1338.

  • 16

    Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2018; 390: 2779–2789.

  • 17

    D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18: 2218–2224.

  • 18

    Josué V, Chaparro M, Gisbert JP. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. Dig Liver Dis. 2018; 50: 353–359.

  • 19

    Falvey J, Gearry R, Day A. Fecal calprotectin does not predict endoscopic remission in inflammatory bowel disease. Inflamm Bowel Dis. 2013; 19: 80–81.

  • 20

    Arai T, Takeuchi K, Miyamura M, et al. Level of fecal calprotectin correlates with severity of small bowel Crohn’s disease, measured by balloon-assisted enteroscopy and computed tomography enterography. Clin Gastroenterol Hepatol. 2017; 15: 56–62.

  • 21

    Kristensen V, Røseth A, Ahmad T, et al. Fecal calprotectin: a reliable predictor of mucosal healing after treatment for active ulcerative colitis. Gastroenterol Res Pract. 2017; 2017: 2098293.

  • 22

    Mak WY, Buisson A, Andersen M, J et al. Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis. Dig Dis Sci. 2018; 63:1294–1301.

  • 23

    European Crohn’s and Colitis Organisation. Published ECCO Guidelines. Vienna, 2017. Available from: https://www.ecco-ibd.eu/publications/ecco-guidelines-science/published-ecco-guidelines.html

  • 24

    Kim J, Kim H, Oh HJ, et al. Fecal calprotectin level reflects the severity of Clostridium difficile infection. Ann Lab Med. 2017; 37: 53–57.

  • 25

    Gallo A, Vallone C, Sabatelli L, et al. Fecal calprotectin in management of Clostridium difficile infection: a longitudinal study. Scand J Gastroenterol. 2018; 53: 567–572.

  • 26

    Peretz A, Tkhawkho L, Pastukh N, et al. Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection. BMC Infect Dis. 2016; 16: 309.

  • 27

    Shastri Y, Bergis D, Povse N, et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med. 2008; 121: 1099–1106.

  • 28

    Duman M, Gencpinar P, Biçmen M, et al. Fecal calprotectin: can be used to distinguish between bacterial and viral gastroenteritis in children? Am J Emerg Med. 2015; 33: 1436–1439.

  • 29

    D’Incà R, Dal Pont E, Di Leo V, al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007; 22: 429–437.

  • 30

    Fu Y, Wang L, Xie C, et al. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep. 2017; 7: 2669.

  • 31

    Schoepfer A, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008; 14: 32–39.

  • 32

    Von Arnim U, Wex T, Ganzert C, et al. Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol. 2016; 9: 97–103.

  • 33

    Moussa R, Khashana A, Kamel N, et al. Fecal calprotectin levels in preterm infants with and without feeding intolerance. J Pediatr. 2016; 92: 486–492.

  • 34

    Balamtekin N, Baysoy G, Uslu N, et al. Fecal calprotectin concentration is increased in children with celiac disease: relation with histopathological findings. Turk J Gastroenterol. 2012; 23: 503–508.

  • 35

    Seo SC, Ahn HS, Ri S, et al. Elevated fecal calprotectin levels are associated with severity of atopic dermatitis in children. Asian Pac J Allergy Immunol. 2018; 36: 82–87.

  • 36

    Savino F, Cordisco L, Tarasco V, et al. Molecular identification of coliform bacteria from colicky breastfed infants. Acta Paediatr. 2009; 98: 1582–1588.

  • 37

    Fatheree NY, Liu Y, Taylor CM, et al. Lactobacillus reuteri for infants with colic: a double-blind, placebo-controlled, randomized clinical trial. J Pediatr. 2017; 191: 170–178.e2.

  • 38

    Tibble J, Sigthorsson G, Foster R, et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001; 49: 402–408.

  • 39

    Ye X, Huai J, Ding J. Diagnostic accuracy of fecal calprotectin for screening patients with colorectal cancer: a meta-analysis. Turk J Gastroenterol 2018; 29: 397–405.

  • 40

    Bonnin Tomàs A, Vila Vidal M, Rosell Camps A. Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease. Rev Esp Enferm Dig. 2007; 99: 689–693.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2021 0 11 81
Feb 2021 0 14 91
Mar 2021 0 29 82
Apr 2021 0 21 84
May 2021 0 20 85
Jun 2021 0 6 43
Jul 2021 0 0 0